$150,000 of NATERA INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Advocacy on importance of FDA's oversight of Laboratory Developed Tests and impact on industry and patients. Advocacy on CMS administrative procedures regarding Date of Service (DOS) for Laboratory testing for patients."
You can find more data on corporate lobbying on Quiver Quantitative.
NTRA Insider Trading Activity
NTRA insiders have traded $NTRA stock on the open market 258 times in the past 6 months. Of those trades, 0 have been purchases and 258 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 50 sales selling 308,708 shares for an estimated $61,652,899.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 32 sales selling 226,953 shares for an estimated $51,860,218.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 35 sales selling 94,026 shares for an estimated $22,564,856.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 21 sales selling 79,769 shares for an estimated $18,738,853.
- ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 35 sales selling 50,504 shares for an estimated $11,458,574.
- JONATHAN SHEENA has made 0 purchases and 61 sales selling 30,779 shares for an estimated $6,547,529.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 11 sales selling 27,575 shares for an estimated $6,339,337.
- HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
- GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
- ROWAN E CHAPMAN has made 0 purchases and 2 sales selling 3,086 shares for an estimated $665,884.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
NTRA Hedge Fund Activity
We have seen 343 institutional investors add shares of NTRA stock to their portfolio, and 335 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,312,887 shares (+12.1%) to their portfolio in Q1 2026, for an estimated $262,564,271
- FMR LLC added 1,078,266 shares (+73.1%) to their portfolio in Q1 2026, for an estimated $215,642,417
- FARALLON CAPITAL MANAGEMENT LLC removed 707,000 shares (-18.1%) from their portfolio in Q1 2026, for an estimated $141,392,930
- DUQUESNE FAMILY OFFICE LLC added 552,249 shares (+22.0%) to their portfolio in Q1 2026, for an estimated $110,444,277
- CASTLE HOOK PARTNERS LP added 361,941 shares (+16.7%) to their portfolio in Q1 2026, for an estimated $72,384,580
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 341,574 shares (-54.6%) from their portfolio in Q1 2026, for an estimated $68,311,384
- MAPLELANE CAPITAL, LLC added 339,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $67,796,610
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
NTRA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 06/23/2026
- William Blair issued a "Outperform" rating on 04/14/2026
To track analyst ratings and price targets for NTRA, check out Quiver Quantitative's $NTRA forecast page.
NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 12 analysts offer price targets for $NTRA in the last 6 months, with a median target of $270.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $310.0 on 07/09/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $300.0 on 07/06/2026
- Subbu Nambi from Guggenheim set a target price of $290.0 on 06/29/2026
- Eve Burstein from Bernstein set a target price of $310.0 on 06/26/2026
- Luke Sergott from Barclays set a target price of $260.0 on 06/24/2026
- Mark Massaro from BTIG set a target price of $275.0 on 06/24/2026
- Dan Leonard from RBC Capital set a target price of $275.0 on 06/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
